Optimark and Cfa - a phase IV clinical study of FDA data

Summary:

Cfa is reported as a side effect among people who take Optimark (gadoversetamide), especially for people who are male, 10-19 old, have been taking the drug for < 1 month also take Magnevist, and have Nuclear magnetic resonance imaging brain.

The phase IV clinical study analyzes which people have Cfa when taking Optimark. It is created by eHealthMe based on reports of 3,054 people who have side effects when taking Optimark from the FDA, and is updated regularly.

What is Optimark?

Optimark has active ingredients of gadoversetamide. eHealthMe is studying from 3,055 Optimark users. Check the latest studies of Optimark.

What is Cfa?

Cfa is found to be associated with 2,091 drugs and 2,244 conditions by eHealthMe. Check the latest studies of Cfa.

On Jan, 11, 2026

3,054 people reported to have side effects when taking Optimark.
Among them, 14 people (0.46%) have Cfa.

Among these 14 people:

How long have people been on Optimark when they have Cfa? *

What is the gender of people who have Cfa when taking Optimark? *

female: 35.71 %
male: 64.29 %

What is the age of people who have Cfa when taking Optimark? *

What are other drugs people take besides Optimark? *

What are other side effects people have besides Cfa? *

Nephrogenic Systemic Fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease): 14 people, 100.00%
Skin Induration (an abnormally hard spot or area on the skin): 12 people, 85.71%
Pain: 11 people, 78.57%
Skin Tightness: 11 people, 78.57%
Fibrosis (formation of excess fibrous connective tissue in an organ or tissue): 9 people, 64.29%
Joint Contracture (a permanent shortening of a muscle or joint): 8 people, 57.14%
Oedema Peripheral (superficial swelling): 7 people, 50.00%
Extremity Contracture (permanent shortening of a muscle or joint of arms and legs): 7 people, 50.00%
Pain In Extremity: 7 people, 50.00%
Mobility Decreased (ability to move is reduced): 7 people, 50.00%

What are the existing conditions these people have? *

Nuclear Magnetic Resonance Imaging Brain: 4 people, 28.57%
Renal Osteodystrophy (a bone disease occurs when the kidneys fail to maintain the proper levels of calcium and phosphorus in the blood): 3 people, 21.43%
Joint Pain: 3 people, 21.43%
Hypercalcaemia (elevated calcium (ca+) level in the blood): 3 people, 21.43%
Headache (pain in head): 3 people, 21.43%
Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body): 3 people, 21.43%
Anaemia (lack of blood): 3 people, 21.43%
Pulmonary Hypertension (increase in blood pressure in the lung artery): 2 people, 14.29%
Diabetes: 2 people, 14.29%
Catheter Related Complication: 2 people, 14.29%

* Approximation only. Some reports may have incomplete information.

Do you take Optimark and have Cfa?

- Check whether Cfa is associated with a drug or a condition (FREE)
- Predict drug outcomes for up to one year with AI (FREE)
- Get an AI agent to monitor your drugs continuously (FREE)

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Optimark:

Optimark (3,055 reports)

Cfa treatments and more:

Cfa (79,192 reports)

Browse all side effects of Optimark:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Cfa:

Cfa (2,090 drugs)

Browse all the conditions that are associated with Cfa:

Cfa (2,244 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on gadoversetamide (the active ingredients of Optimark) and Optimark (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.